Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Screeners that run automatically... and then email you the results! FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Amryt Pharma Plc ADR (AMYT)

Amryt Pharma Plc ADR (AMYT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 484,200
  • Shares Outstanding, K 63,963
  • Annual Sales, $ 222,540 K
  • Annual Income, $ 1,000 K
  • 60-Month Beta 0.33
  • Price/Sales 2.16
  • Price/Cash Flow 7.81
  • Price/Book 1.42
Trade AMYT with:

Options Overview Details

View History
  • Implied Volatility 114.43% ( +0.48%)
  • Historical Volatility 27.44%
  • IV Percentile 86%
  • IV Rank 39.37%
  • IV High 288.01% on 06/06/22
  • IV Low 1.72% on 07/20/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 2
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 622
  • Open Int (30-Day) 605

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.03
  • Number of Estimates 2
  • High Estimate -0.01
  • Low Estimate -0.05
  • Prior Year -0.07
  • Growth Rate Est. (year over year) +57.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.00 +8.14%
on 08/01/22
8.17 -7.34%
on 08/08/22
+0.09 (+1.20%)
since 07/15/22
3-Month
6.41 +18.10%
on 06/21/22
8.21 -7.80%
on 05/17/22
-0.43 (-5.37%)
since 05/16/22
52-Week
5.61 +34.94%
on 02/28/22
12.45 -39.20%
on 10/04/21
-3.40 (-30.99%)
since 08/16/21

Most Recent Stories

More News
Can Amryt Pharma PLC Sponsored ADR (AMYT) Climb 187% to Reach the Level Wall Street Analysts Expect?

The mean of analysts' price targets for Amryt Pharma PLC Sponsored ADR (AMYT) points to an 187.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong...

AMYT : 7.57 (+0.66%)
Amryt Pharma PLC Sponsored ADR (AMYT) Reports Q2 Loss, Tops Revenue Estimates

Amryt Pharma PLC Sponsored ADR (AMYT) delivered earnings and revenue surprises of 50% and 9.55%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?...

AMYT : 7.57 (+0.66%)
MRSN : 7.23 (-6.23%)
Amryt to Report Q2 2022 Results on August 4, 2022

DUBLIN, Ireland, and Boston MA, July 21, 2022, Amryt (Nasdaq: AMYT) a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing...

AMYT : 7.57 (+0.66%)
Amryt (AMYT) Mycapssa Gets Orphan Drug Tag for Carcinoid Syndrome

The FDA bestows an Orphan Drug designation to Amryt's (AMYT) Mycapssa for the treatment of carcinoid syndrome. Stock up in pre-market trading.

FATE : 32.90 (-8.76%)
LPTX : 1.3900 (-2.80%)
DTIL : 1.99 (-3.40%)
AMYT : 7.57 (+0.66%)
Amryt Receives Orphan Drug Designation from the FDA for Mycapssa® (oral octreotide) for the Treatment of Carcinoid Syndrome

Amryt Receives Orphan Drug Designation from the FDA for Mycapssa® (oral octreotide) for the Treatment of Carcinoid Syndrome DUBLIN, Ireland, and Boston...

AMYT : 7.57 (+0.66%)
Amryt Presents New Analyses from the EASE Phase 3 Trial in Epidermolysis Bullosa at SPD 2022

Amryt Presents New Analyses from the EASE Phase 3 Trial in Epidermolysis Bullosa at SPD 2022 - Key highlights include efficacy of Oleogel-S10 (birch...

AMYT : 7.57 (+0.66%)
Results of Annual General Meeting

DUBLIN, Ireland, and Boston MA, July 1, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing...

AMYT : 7.57 (+0.66%)
Amryt Announces Appointment of Dr Tracy Cunningham as Chief Medical Officer

Amryt Announces Appointment of Dr Tracy Cunningham as Chief Medical Officer DUBLIN, Ireland, and Boston MA, June 27, 2022, Amryt (Nasdaq: AMYT), a global,...

AMYT : 7.57 (+0.66%)
Amryt Announces Appointment of Dr Tracy Cunningham as Chief Medical Officer

Amryt Announces Appointment of Dr Tracy Cunningham as Chief Medical Officer DUBLIN, Ireland, and Boston MA, June 27, 2022, Amryt (Nasdaq: AMYT), a global,...

AMYT : 7.57 (+0.66%)
Amryt Pharma PLC Sponsored ADR (AMYT) Surges 7.5%: Is This an Indication of Further Gains?

Amryt Pharma PLC Sponsored ADR (AMYT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further...

AMYT : 7.57 (+0.66%)
LUMO : 8.85 (+1.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Amryt Pharma plc is a biopharmaceutical company. It develops and commercializes therapeutics to treat rare diseases. Amryt Pharma plc is based in London, the United Kingdom.

See More

Key Turning Points

3rd Resistance Point 7.91
2nd Resistance Point 7.80
1st Resistance Point 7.69
Last Price 7.57
1st Support Level 7.47
2nd Support Level 7.36
3rd Support Level 7.25

See More

52-Week High 12.45
Fibonacci 61.8% 9.84
Fibonacci 50% 9.03
Fibonacci 38.2% 8.22
Last Price 7.57
52-Week Low 5.61

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar